Results 71 to 80 of about 14,163 (275)

Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases

European Journal of Heart Failure, Volume 24, Issue 11, Page 2000-2018, November 2022., 2022
Overview on incidence, diagnosis, and therapy in vaccine‐related myocarditis. CMR, cardiac magnetic resonance; EMB, endomyocardial biopsy; NSAIDS, non‐steroidal anti‐inflammatory drugs. Abstract Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide.
Bettina Heidecker, Noa Dagan, Ran Balicer, Urs Eriksson, Giuseppe Rosano, Andrew Coats, Carsten Tschöpe, Sebastian Kelle, Gregory A. Poland, Andrea Frustaci, Karin Klingel, Pilar Martin, Joshua M. Hare, Leslie T. Cooper, Antonis Pantazis, Massimo Imazio, Sanjay Prasad, Thomas F. Lüscher   +17 more
wiley   +1 more source

Tripchlorolide attenuates β-amyloid generation by inducing NEP activity in N2a/APP695 cells

Translational Neuroscience, 2021
Alzheimer’s disease (AD) is a neurodegeneration disease. The previous work from our research group demonstrated the neuroprotective effects of tripchlorolide (T4) in AD animal models.
Zeng Yuqi, Li Yongkun, Shen Hui, Lin Nan, Zhang Jian   +4 more
doaj   +1 more source

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]

, 2017
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan, Desai, Akshay S., Dukát, Andrej, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Lefkowitz, Martin P., McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Prescott, Margaret F., Ramires, Felix, Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl   +16 more
core   +3 more sources

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries

European Journal of Heart Failure, Volume 24, Issue 11, Page 2066-2077, November 2022., 2022
Hospital performance and outcomes according to the 2021 European Society of Cardiology (ESC) quality indicators for heart failure (HF). ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; HFrEF, heart failure ...
Gorav Batra, Suleman Aktaa, Lina Benson, Ulf Dahlström, Camilla Hage, Gianluigi Savarese, Peter Vasko, Chris P. Gale, Lars H. Lund   +8 more
wiley   +1 more source

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy

ESC Heart Failure, 2022
To assess the effect of angiotensin receptor blockers/neprilysin inhibitors (ARNI) on left ventricular (LV) ejection fraction (LVEF) and LV dimensions in a real‐life cohort of heart failure and reduced ejection fraction (HFrEF) patients, while analysing ...
L. Maizels, Y. Wasserstrum, B. Fishman, A. Segev, David Ben-Nun, Anan Younis, D. Freimark, I. Mazin, A. Grupper   +8 more
semanticscholar   +1 more source

INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY

Медицинский совет, 2017
The article is devoted to the innovative drug to treat chronic cardiac insufficiency – a combination of sakubitril neprilysin inhibitor and first type angiotension II receptor antagonist valsartan (sacubitril/valsartan).
N. A. Jaiani
doaj   +1 more source

Adipolin, Chemerin, Neprilysin and Metabolic Disorders Associated with Obesity

Applied Sciences, 2023
Adipolin, neprilysin, and chemerin have pleiotropic properties; therefore, their concentrations may influence health complications associated with obesity.
Marcelina Sperling, Teresa Grzelak, Marta Pelczyńska, Paweł Bogdański, Krystyna Czyżewska, Dorota Formanowicz   +5 more
doaj   +1 more source

Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial [PDF]

, 2016
Objectives: This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability. Background: Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ...
Claggett, Brian, Desai, Akshay, Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rouleau, Jean, Shi, Victor, Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +9 more
core   +2 more sources

The Association between Neprilysin gene polymorphisms and Alzheimer’s disease in Tibetan population

Brain and Behavior, 2021
Objectives Alzheimer's disease (AD) is a well‐known neurodegenerative disease, of which the hallmark is the disposition of β‐amyloid (Aβ) in the form of plaque in the brain.
Siwei Chen, Dunzhu Mima, Haiqiang Jin, Qu Dan, Fei Wang, Juan Cai, Lin Shi, Huali Wang, Ailian Du, Ying Tang, Yongan Sun   +10 more
doaj   +1 more source